The endocannabinoid system and the treatment of obesity

被引:71
作者
Pagotto, U
Vicennati, V
Pasquali, R
机构
[1] Orsola Malpighi Gen Hosp, Dept Internal Med & Gastroenterol, Endocrinol Unit, I-40138 Bologna, Italy
[2] Orsola Malpighi Gen Hosp, Dept Internal Med & Gastroenterol, Ctr Appl Biomed Res, I-40138 Bologna, Italy
关键词
CB1; receptor; endocannabinoid system; obesity; rimonabant;
D O I
10.1080/07853890510037419
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The endocannabinoids are endogenous lipids capable of binding to both cannabinoid receptors (CB) CB1 and CB2. These receptors belong to the G protein-coupled family receptors and they were discovered while investigating the mode of action of Delta(9)-tetrahydrocannabinol, a component of Cannabis sativa, to which they bind with high affinity. Among many other brain sites, CB1 is present in the hypothalamic nuclei involved in the control of energy balance and body weight, as well as in neurons of the mesolimbic system which is believed to mediate the incentive value of food. At central nervous system level, CB I activation is necessary to induce food intake after a short period of food deprivation, and when CB1 is activated by endocannabinoids produced in situ, a stimulation of the ingestion of palatable food has been described. CB I stimulation leads to modulation of the release of some hypothalamic anorexigenic and orexigenic mediators, as well as of dopamine in the nucleus accumbens shell. Recent evidence has proved that CB1 is also present in the peripheral organs, such as the adipose tissue and gastrointestinal system, key organs in the regulation of energy metabolism. Animal models have provided solid evidence that genetically induced obesity leads to long-lasting overstimulation of endocannabinoid system synthesis resulting in permanent overactivation of CB 1, which may then contribute to the maintenance of this disease. Importantly, at peripheral level, CB I activation has been shown to stimulate lipogenesis in adipocytes. CB I blockers increase adiponectin production in adipocytes, which leads to increased fatty acid oxidation and free fatty acid clearance. Moreover, CB1 has been shown to be up-regulated in adipocytes derived from obese rodents. These results support the role of endocannabinoids in the development and maintenance of obesity, paving the way for the development of a new class of drugs such as the CB I blockers as a therapy for tackling obesity and the associated major cardiovascular risk factors.
引用
收藏
页码:270 / 275
页数:6
相关论文
共 59 条
  • [1] CANNABIS - EFFECTS ON HUNGER AND THIRST/EUM OF
    ABEL, EL
    [J]. BEHAVIORAL BIOLOGY, 1975, 15 (03): : 255 - 281
  • [2] Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors
    Arnone, M
    Maruani, J
    Chaperon, F
    Thiebot, MH
    Poncelet, M
    Soubrie, P
    LeFur, G
    [J]. PSYCHOPHARMACOLOGY, 1997, 132 (01) : 104 - 106
  • [3] Endocannabinoids acting at vascular CB, receptors mediate the vasodilated state in advanced liver cirrhosis
    Bátkai, S
    Járat, Z
    Wagner, JA
    Goparaju, SK
    Varga, K
    Liu, J
    Wang, L
    Mirshahi, F
    Khanolkar, AD
    Makriyannis, A
    Urbaschek, R
    Garcia, N
    Sanyal, AJ
    Kunos, G
    [J]. NATURE MEDICINE, 2001, 7 (07) : 827 - 832
  • [4] Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia
    Beal, JE
    Olson, R
    Lefkowitz, L
    Larenstein, L
    Bellman, P
    Yangco, B
    Morales, JO
    Murphy, R
    Powderly, W
    Plasse, TF
    Mosdell, KW
    Shepard, KV
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 14 (01) : 7 - 14
  • [5] The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells
    Bensaid, M
    Gary-Bobo, M
    Esclangon, A
    Maffrand, JP
    Le Fur, G
    Oury-Donat, F
    Soubrié, P
    [J]. MOLECULAR PHARMACOLOGY, 2003, 63 (04) : 908 - 914
  • [6] Food reward: Brain substrates of wanting and liking
    Berridge, KC
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1996, 20 (01) : 1 - 25
  • [7] Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin
    Burdyga, G
    Lal, S
    Varro, A
    Dimaline, R
    Thompson, DG
    Dockray, GJ
    [J]. JOURNAL OF NEUROSCIENCE, 2004, 24 (11) : 2708 - 2715
  • [8] Chambers AP, 2004, PHYSIOL BEHAV, V82, P863, DOI 10.1016/S0031-9384(04)00302-6
  • [9] Adiponectin: More than just another fat cell hormone?
    Chandran, M
    Phillips, SA
    Ciaraldi, T
    Henry, RR
    [J]. DIABETES CARE, 2003, 26 (08) : 2442 - 2450
  • [10] Cota D, 2003, J CLIN INVEST, V112, P423, DOI [10.1172/JCI200317725, 10.1172/JCI17725]